Biotech Values

[turtlepower]

That's a good catch. I hadn't noticed that. That does raise questions about the trial, at least to me. It looks like perhaps they may have excluded most of the 2nd line patients who may have enrolled, from the final data analysis?? Also CRC isn't that rare so being able to enroll only 38 patients in a span of 5 years is somewhat surprising. Especially for a treatment that appears to have had substantial benefit.